Obesity is an epidemic and a public health threat. Medical weight management remains one
of the options for the treatment of excess weight and recent advances have revolutionized …

Background Pharmacotherapy provides an option for adults with overweight and obesity to
reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …

Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …

Importance The effect of continued treatment with tirzepatide on maintaining initial weight
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical …

Importance Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like
peptide-1 analogues available for weight management. Objective To compare the efficacy …

Importance Obesity affects approximately 42% of US adults and is associated with increased
rates of type 2 diabetes, hypertension, cardiovascular disease, sleep disorders …

Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …